Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics Plc ADR (NQ: AUTL ) 3.980 +0.300 (+8.15%) Streaming Delayed Price Updated: 2:18 PM EDT, May 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 5,914,783 Open 3.680 Bid (Size) 3.980 (10) Ask (Size) 3.990 (7) Prev. Close 3.680 Today's Range 3.625 - 3.995 52wk Range 1.780 - 7.450 Shares Outstanding 52,346,231 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO April 24, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 April 23, 2024 From Autolus Therapeutics plc Via GlobeNewswire Performance YTD -41.81% -41.81% 1 Month -29.93% -29.93% 3 Month -32.08% -32.08% 6 Month +41.13% +41.13% 1 Year +113.98% +113.98% More News Read More 12 Health Care Stocks Moving In Thursday's After-Market Session April 11, 2024 Via Benzinga Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views March 18, 2024 Via Benzinga Autolus Therapeutics's Earnings Outlook March 13, 2024 Via Benzinga Analyst Expectations for Autolus Therapeutics's Future December 13, 2023 Via Benzinga Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia April 02, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Changes to its Board of Directors April 01, 2024 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 20, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session March 15, 2024 Via Benzinga Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates March 14, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site March 12, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Blood Cancer Journal March 11, 2024 From Autolus Therapeutics plc Via GlobeNewswire Earnings Scheduled For March 14, 2024 March 14, 2024 Via Benzinga Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 February 29, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Nature Communications February 22, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Announces Pricing of Underwritten Offering February 08, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in ACS Chemical Biology January 23, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL) January 22, 2024 From Autolus Therapeutics plc Via GlobeNewswire Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments January 12, 2024 Via Talk Markets Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors January 10, 2024 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session December 27, 2023 Via Benzinga Autolus Therapeutics Announces Changes to its Board of Directors December 22, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 December 09, 2023 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session November 28, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
